Korro Bio Analyst Price Targets - Benzinga

Korro Bio Inc

KRRONASDAQ

Trade with Public

Trade with Public

$10.37

-0.21-1.98%

Últ. Act.: Oct 9, 1:39 PM

$10.61

0.030.28%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Korro Bio Analyst Price Targets - Benzinga

Korro Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Korro Bio (KRRO).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

10Buy

2Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$37Upside to Avg. PT+252.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$15
Aug 20, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$15
May 19, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$20→$15
May 18, 2026	Citigroup	Yigal Nochomovitz	Initiate	Buy	$21
Mar 13, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$21→$22
Mar 13, 2026	Raymond James	Steven Seedhouse	Upgrade	Market Perform→Outperform	$23
Feb 19, 2026	Clear Street	Bill Maughan	Upgrade	Hold→Buy	$10→$18
Feb 17, 2026	William Blair	Myles Minter	Upgrade	Market Perform→Outperform	—
Jan 29, 2026	Piper Sandler	Yasmeen Rahimi	Upgrade	Neutral→Overweight	$11→$30
Jan 29, 2026	Chardan Capital	Keay Nakae	Upgrade	Neutral→Buy	$7→$15
Jan 29, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Upgrade	Neutral→Buy	$20
Jan 28, 2026	Oppenheimer	Kostas Biliouris	Upgrade	Perform→Outperform	$22
Jan 28, 2026	Cantor Fitzgerald	Steve Seedhouse	Upgrade	Neutral→Overweight	$21
Nov 14, 2025	Jones Trading	Catherine Novack	Downgrade	Buy→Hold	—
Nov 13, 2025	William Blair	Myles Minter	Downgrade	Outperform→Market Perform	—
Nov 13, 2025	RBC Capital	Luca Issi	Downgrade	Outperform→Sector Perform	$85→$8
Nov 13, 2025	Chardan Capital	Keay Nakae	Downgrade	Buy→Neutral	$25→$7
Nov 13, 2025	Cantor Fitzgerald	Steve Seedhouse	Downgrade	Overweight→Neutral	—
Nov 13, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Downgrade	Buy→Neutral	—
Oct 31, 2025	Clear Street	Bill Maughan	Initiate	Buy	$93

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Korro Bio, Lowers Price Target to $15

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Korro Bio (NASDAQ:KRRO) with a Buy and lowers the price target from $20 to $15.

Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $21

Citigroup analyst Yigal Nochomovitz initiates coverage on Korro Bio (NASDAQ:KRRO) with a Buy rating and announces Price Target of $21.

Benzinga Newsdesk

Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook

Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and long-term growth plans.

Vandana Singh

PRO
Cantor Fitzgerald Maintains Overweight on Korro Bio, Raises Price Target to $22

Cantor Fitzgerald analyst Steve Seedhouse maintains Korro Bio (NASDAQ:KRRO) with a Overweight and raises the price target from $21 to $22.

Benzinga Newsdesk